AbbVie’s new AI deal; Roche's PhIII win in breast cancer; SpringWorks to raise $275M
Plus, news about Eligo Bioscience, EyePoint, Xenon and Merus:
AbbVie signs AI pact: For $30 million upfront, the pharma is partnering with BigHat Biosciences to develop new antibodies in oncology and neuroscience. It’s the second biopharma AI alliance to be announced on Tuesday. AbbVie could dish out up to $325 million more in R&D milestones. — Kyle LaHucik
Roche touts PhIII breast cancer win for PI3K alpha drug: The Big Pharma’s inavolisib plus Pfizer’s Ibrance achieved a statistically significant improvement in the primary endpoint of progression-free survival in people with PIK3CA-mutated HR-positive HER2-negative advanced or metastatic disease. Roche plans to present the full data at a future meeting and then submit them to health authorities. — Ayisha Sharma
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.